-
缺血性心脏病患者因心肌缺血、缺氧而发生心肌梗死, 给社会及家庭带来了极大的痛苦和经济负担。随着经济发展和人民生活方式的改变, 我国冠心病的发病率和病死率呈上升趋势[1-3]。目前, 冠心病的常规治疗方法包括药物治疗、血管重建治疗(如冠状动脉旁路移植术、经皮冠状动脉腔内成形术等)、干细胞移植治疗及其他治疗。药物虽然可以延缓缺血性心脏病的进展, 但并不能阻止病变的进程, 大多数患者最终仍因心力衰竭而死亡。手术及介入治疗不断发展完善, 有效地延缓了缺血性心脏病的进展, 但是术后并发症仍存在, 仍不能有效修复或替代业已坏死的心肌、促进心肌细胞的再生。心脏移植术成为患者发生心力衰竭后最终的治疗方法, 但是要找到合适的捐赠者的心脏需要花费太长的时间, 这就促使我们必须寻求到一种更好的治疗方法。随着分子生物学和细胞生物学的发展完善, 基因治疗成为治疗缺血性心脏病的新方向。
促血管生成因子在治疗缺血性心脏病中的应用
Utility of the angiogenesis factors in the management of ischemic heart disease
-
摘要: 缺血性心脏病严重危害着人类的健康, 目前使用的常规治疗方法仍无法修复坏死的心肌, 达到满意的治疗效果。基因治疗尤其是促血管生成因子的治疗为此类疾病的治愈带来了希望。该文就促血管生成因子基因治疗缺血性心脏病的研究进展进行综述。Abstract: Ischemic heart disease seriously damages people′s health. Current therapies present a major challenge in the treatment of myocardium infarction, and can′t achieve satisfactory therapeutic effect. Gene therapy especially the angiogenesis factors offered new hopes to treat the disease. In addition, this paper summarizes the research advance in the therapeutic effect of the angiogenesis factors on ischemic heart disease.
-
Key words:
- Myocardial ischemia /
- Angiogenesis inducing agents /
- Gene therapy
-
[1] 张海澄, 郭继鸿.冠心病流行病学与一级预防.中国实用内科杂志, 2002, 22(8): 449-451.
[2] 吴锡桂.我国人群冠心病流行现况与趋势.中国慢性病预防与控制, 2003, 11(4): 190-191.
[3] 刘小清.冠心病流行病学研究进展及疾病负担.中华心血管病杂志, 2008, 36(6): 573-576.
[4] Taimeh Z, Loughran J, Birks EJ, et al. Vascular endothelial growth factor in heart failure. Nat Rev Cardiol, 2013, 10(9): 519-530. [5] Woolard J, Bevan HS, Harper SJ, et al. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation, 2009, 16(7): 572-592. [6] Zhao T, Zhao W, Chen Y, et al. Vascular endothelial growth factor(VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc Res, 2010, 80(2): 188-194. [7] Nam JO, Son HN, Jun E, et al. FAS1 domain protein inhibits VEGF165-induced angiogenesis by targeting the interaction between VEGFR-2 and αvβ3 integrin. Mol Cancer Res, 2012, 10(8): 1010-1020. [8] Ruixing Y, Jiaquan L, Jie C, et al. Intravenous administration of vascular endothelial growth factor improves cardiac performance and inhibits cardiomyocyte apoptosis. Growth Factors, 2006, 24(3): 209-217. [9] Hao X, Månsson-Broberg A, Grinnemo KH, et al. Myocardial angiogenesis after plasmid or adenoviral VEGF-A165 gene transfer in rat myocardial infarction model. Cardiovasc Res, 2007, 73(3): 481-487. [10] Yan D, Wang X, Li D, et al. Macrophages overexpressing VEGF target to infarcted myocardium and improve neovascularization and cardiac function. Int J Cardiol, 2013, 164(3): 334-338. [11] Morishita R, Aoki M, Yo Y, et al. Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Endocr J, 2002, 49(3): 273-284. [12] Salimath AS, Phelps EA, Boopathy AV, et al. Dual delivery of hepatocyte and vascular endothelial growth factors via a protease-degradable hydrogel improves cardiac function in rats[J/OL]. PLoS One, 2012, 7(11): e50980[2012-12-24]. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0050980. [13] Paradiso B, Zucchini S, Simonato M. Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements[J/OL]. Front Cell Neurosci, 2013, 7: 1-9[2012-12-24]. http://www.readcube.com/articles/10.3389/fncel.2013.00152. [14] Gao MH, Lai NC, McKirnan MD, et al. Increased regional function and perfusion after intracoronary delivery of adenovirus encoding fibroblast growth factor 4: report of preclinical data. Hum Gene Ther, 2004, 15(6): 574-587. [15] Suzuki G, Lee TC, Fallavollita JA, et al. Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle. Circ Res, 2005, 96(7): 767-775. [16] McCarter SD, Mei SH, Lai PF, et al. Cell-based angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care Med, 2007, 175(10): 1014-1026. [17] Mei SH, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1[J/OL]. PLoS Med, 2007, 4(9): e269[2012-12-24]. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0040269. [18] 朱成楚, 陈仕林, 刘玉清, 等. rAAV2VEGF165与rAAV2ANG-1联合转染促猪缺血心肌血管生成的研究.浙江大学学报:医学版, 2010, 39(6): 610-617.
[19] 黄盛东, 刘晓红, 白辰光, 等.重组腺病毒介导的血管生成素改善缺血性心脏病的实验研究.中华老年心脑血管病杂志, 2007, 9(3): 192-195.
[20] 王潇, 陈茜, 周青, 等. SonoVue微泡介导转染Ang-1基因治疗急性心肌梗死.中国医学影像技术, 2009, 25(11): 1969-1971.
[21] Tuo QH, Xiong GZ, Zeng H, et al. Angiopoietin-1 protects myocardial endothelial cell function blunted by angiopoietin-2 and high glucose condition. Acta pharmacol Sin, 2011, 32(1): 45-51. [22] Tao Z, Chen B, Tan X, et al. Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction(MI)heart. Proc Natl Acad Sci U S A, 2011, 108(5): 2064-2069. [23] Yuan G, Peng YJ, Reddy VD, et al. Mutual antagonism between hypoxia-inducible factors 1α and 2α regulates oxygen sensing and cardio-respiratory homeostasis. Proc Natl Acad Sci U S A. 2013, 110(19): E1788-1796. [24] D'Angelo G, Duplan E, Boyer N, et al. Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem, 2003, 278(40): 38183-38187. [25] Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995, 92(12): 5510-5514. [26] Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood, 2005, 105(2): 659-669. [27] Semenza GL. Hypoxia-inducible factor 1(HIF-1) pathway[J/OL]. Sci STKE, 2007, 2007(407): cm8[2012-12-24]. http://stke.sciencemag.org/cgi/content/abstract/2007/407/cm8. [28] Brahimi-Horn C, Pouysségur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer, 2006, 93(8): E73-80. [29] Hinkel R, Lebherz C, Fydanaki M, et al. Angiogenetic potential of Ad2/Hif-1α/VP16 after regional application in a preclinical pig model of chronic ischemia. Curr Vasc Pharmacol. 2013, 11(1): 29-37. [30] 牛铁生.缺氧诱导因子1对大鼠心肌梗死及再灌注损伤的保护作用研究.沈阳: 中国医科大学, 2007.
[31] Huang Y, Hickey RP, Yeh JL, et al. Cardiac myocyte-specific HIF-1α deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J. 2004, 18(10): 1138-1140. [32] Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation, 2001, 103(17): 2138-2143. [33] Shyu KG, Wang MT, Wang BW, et al. Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res, 2002, 54(3): 576-583. [34] Dong F, Khalil M, Kiedrowski M, et al. Critical role for leukocyte hypoxia inducible factor-1α expression in post-myocardial infarction left ventricular remodeling. Circ Res, 2010, 106(3): 601-610.
计量
- 文章访问数: 2870
- HTML全文浏览量: 1531
- PDF下载量: 2